Resilience Demonstrates Lower Cost of Perfusion Bioreactor Process Using 908 Devices’ REBEL At-line Analyzer
April 26 2023 - 7:00AM
Business Wire
908 Devices Inc., (Nasdaq: MASS), a pioneer of purpose-built
handheld and desktop devices for chemical and biochemical analysis,
announced that National Resilience, Inc. (Resilience), a
technology-focused biomanufacturing company, has adopted REBEL
at-line media analyzers in their process development to inform and
optimize cell culture feed strategies and media design. REBEL
provides insights into cell metabolism to enable Resilience process
engineers to measure spent media samples to monitor amino acid
depletion during a monoclonal antibody perfusion process.
Resilience demonstrated, using REBEL, a 50% increase in titer while
reducing cost of goods by adding back only the nutrients the cells
have depleted.
“Data from the REBEL enables our teams to improve the speed of
development, allowing for rapid optimization of our media feeds,”
said Andy Grube, Director of Upstream Process Development,
Biologics Franchise at Resilience. “Cell culture media and feed
costs are significant in a perfusion process. With at-line media
analysis, we can optimize and accelerate biotherapeutic
development, with the ultimate goal of reducing cost of goods and
time to submission.”
Resilience engineers are researching various techniques to lower
the cost of media used in a perfusion process. At-line media
analysis enables process development engineers to make decisions
throughout the bioreactor run and inform feeding models, thereby
improving cell culture outcomes and maximizing bioreactor
utilization. At-line media analysis may further enable biopharma to
characterize process consistency via media “finger printing” and
process monitoring.
About the REBEL analyzer
REBEL is a first-of-its-kind fresh and spent media analyzer that
enables biopharma researchers to accelerate process development
cycles and maximize bioreactor utilization by running media
analysis at-line. Key benefits include:
- Efficiency – minimal sample preparation and tiny volume
requirements
- Real-time data tracking – quantitate over 30 key media
nutrients in <10 minutes
- Small and simple – versatile design valued by users
across many applications
For more information, visit www.908devices.com.
About Resilience
Resilience is a technology-focused biomanufacturing company
dedicated to broadening access to complex medicines. Founded in
2020, the company is building a sustainable network of high-tech,
end-to-end manufacturing solutions to ensure the treatments of
today and tomorrow can be made quickly, safely, and at scale. By
continuously advancing the science of biopharmaceutical
manufacturing and development, Resilience seeks to free its
partners to focus on the discoveries that improve patients’ lives
and protect biopharmaceutical supply chains against future
disruptions. For more information, visit
https://resilience.com.
About 908 Devices
908 Devices is revolutionizing chemical and biochemical analysis
with its simple handheld and desktop devices, addressing
critical-to-life applications. The Company’s devices are used at
the point-of-need to interrogate unknown and invisible materials
and provide quick, actionable answers to directly address some of
the most critical problems in life sciences research,
bioprocessing, pharma/biopharma, forensics and adjacent markets.
The Company is headquartered in the heart of Boston, where it
designs and manufactures innovative products that bring together
the power of mass spectrometry, microfluidic sampling and
separations, software automation, and machine learning.
Forward Looking Statements
This press release includes “forward looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements other than statements of historical facts are
forward-looking statements, including, without limitation,
statements regarding the expected uses and capabilities of the
Company’s products. Words such as “may,” “will,” “expect,” “plan,”
“anticipate,” “estimate,” “intend” and similar expressions (as well
as other words or expressions referencing future events, conditions
or circumstances) are intended to identify forward-looking
statements. These forward-looking statements are based on
management’s current expectations and involve known and unknown
risks, uncertainties and assumptions which may cause actual results
to differ materially from any results expressed or implied by any
forward-looking statement, including the risks outlined under “Risk
Factors” and elsewhere in the Company’s filings with the Securities
and Exchange Commission which are available on the SEC's website at
www.sec.gov. Additional information will be made available in the
Company’s annual and quarterly reports and other filings that it
makes from time to time with the SEC. Although the Company believes
that the expectations reflected in its forward-looking statements
are reasonable, it cannot guarantee future results. The Company has
no obligation, and does not undertake any obligation, to update or
revise any forward-looking statement made in this press release to
reflect changes since the date of this press release, except as may
be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230426005242/en/
Media Barbara Russo brusso@908devices.com Investor
Carrie Mendivil IR@908devices.com
908 Devices (NASDAQ:MASS)
Historical Stock Chart
From Jul 2024 to Jul 2024
908 Devices (NASDAQ:MASS)
Historical Stock Chart
From Jul 2023 to Jul 2024